Literature DB >> 15087697

Risk factors for recurrent cholangitis after initial hepatolithiasis treatment.

Jin-Hyeok Hwang1, Yong Bum Yoon, Yong-Tae Kim, Jae Hee Cheon, Ji Bong Jeong.   

Abstract

GOALS: To elucidate the risk factors that can affect the rate of cholangitis after hepatolithiasis treatment.
BACKGROUND: Hepatolithiasis is prevalent in East Asia and causes long-term complications. Recurrent cholangitis is one of its most serious complications and can lead to biliary stricture, liver cirrhosis, and even cholangiocarcinoma. However, little is known about the risk factors associated with cholangitis. STUDY: The clinical records of 193 patients with hepatolithiasis who had been newly diagnosed and treated were reviewed. The mean follow-up was 56 months (1-242 months).
RESULTS: Cumulative cholangitis rates were 25.0% at 3 years and 37.0% at 5 years. By multivariate analysis, cholangitis was associated with hepatic resection (Hazard ratio [HR] = 0.28; 95% confidence interval [CI]: 0.12-0.65), residual stones (HR = 1.77; 95% CI: 1.05-2.98), and recurrent stones (HR = 4.02; 95% CI: 1.31-12.36), but not Sphincter of Oddi disruption. Though biliary stricture did not in general affect the cholangitis rate, a stricture located in the common hepatic or common bile duct was associated with a higher rate of cholangitis than a stricture in the intrahepatic duct alone.
CONCLUSIONS: Cholangitis occurs frequently in hepatolithiasis patients with a common hepatic or common bile duct stricture, residual stones, recurrent stones, and in those that are treated by nonhepatic resection.

Entities:  

Mesh:

Year:  2004        PMID: 15087697     DOI: 10.1097/00004836-200404000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  15 in total

1.  Hepatectomy with primary closure of common bile duct for hepatolithiasis combined with choledocholithiasis.

Authors:  Chang-Ku Jia; Jie Weng; You-Ke Chen; Qing-Zhuang Yang; Yu Fu; Qi-Fan Qin; Wei-Ming Yu
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Laparoscopic hepatectomy for hepatolithiasis: a feasibility and safety study in 29 patients.

Authors:  Xiujun Cai; Yifan Wang; Hong Yu; Xiao Liang; Shuyou Peng
Journal:  Surg Endosc       Date:  2007-05-22       Impact factor: 4.584

3.  Favorable outcomes of hilar duct oriented hepatic resection for high grade Tsunoda type hepatolithiasis.

Authors:  Bong-Wan Kim; Hee-Jung Wang; Wook-Hwan Kim; Myung-Wook Kim
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

4.  The safety and feasibility of reoperation for the treatment of hepatolithiasis by laparoscopic approach.

Authors:  Ju Tian; Jian-wei Li; Jian Chen; Yu-dong Fan; Ping Bie; Shu-guang Wang; Shu-guo Zheng
Journal:  Surg Endosc       Date:  2013-01-11       Impact factor: 4.584

5.  Hepaticojejunostomy for hepatolithiasis: a critical appraisal.

Authors:  Shao-Qiang Li; Li-Jian Liang; Bao-Gang Peng; Jia-Ming Lai; Ming-De Lu; Dong-Ming Li
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

6.  Selection of surgical treatment types for intrahepatic duct stones.

Authors:  Kyung Sook Hong; Kyoung Tae Noh; Seog Ki Min; Hyeon Kook Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2011-08-31

7.  Clinical application of plasma shock wave lithotripsy in treating impacted stones in the bile duct system.

Authors:  Zhi Xu; Li-Xin Wang; Neng-Wei Zhang; Chun-Sheng Hou; Xiao-Feng Ling; Yao Xu; Xiao-Si Zhou
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

8.  Laparoscopic left hepatectomy in patients with intrahepatic duct stones and recurrent pyogenic cholangitis.

Authors:  Sunjong Han; Insang Song; Kwangsik Chun
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2012-08-31

Review 9.  Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.

Authors:  Fu Yu Li; Nan Sheng Cheng; Hui Mao; Li Sheng Jiang; Jing Qiu Cheng; Quan Sheng Li; Sanjay Munireddy
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

10.  Treatment of chronic proliferative cholangitis with c-myc shRNA.

Authors:  Fu-Yu Li; Nan-Sheng Cheng; Jing-Qiu Cheng; Hui Mao; Li-Sheng Jiang; Ning Li; Sheng He
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.